Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 6/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NCK1 | P16333 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2756731 | 0.87 | CYP1A2 (0.44) | TYMSMAOACYP1A2CYP2A6LMNA | |
| SCHEMBL12327738 | 0.80 | CYP1A2 (0.46) | TYMSMAOACYP1A2CYP2A6LMNA | |
| SCHEMBL10644678 | 0.79 | TYMS (0.60) | TYMSMAOACYP1A2CYP2A6ALDH1A1 | |
| SCHEMBL15045589 | 0.79 | CYP1A2 (0.42) | TYMSCYP1A2LMNAALDH1A1PARP1 | |
| SCHEMBL13383928 | 0.77 | ALDH1A1 (0.48) | TYMSLMNAALDH1A1POLBKMT2A | |
| SCHEMBL6450968 | 0.76 | TYMS (0.73) | TYMSPARP1 | |
| SCHEMBL13120672 | 0.75 | TYMS (0.41) | TYMSCYP1A2LMNAALDH1A1POLB | |
| SCHEMBL7263029 | 0.74 | KDM4E (0.66) | TYMSLMNAALDH1A1POLBKMT2A | |
| SCHEMBL29535139 | 0.74 | KDM4E (0.66) | TYMSLMNAALDH1A1POLBKMT2A | |
| SCHEMBL13383924 | 0.74 | TYMS (0.44) | TYMSLMNAALDH1A1PARP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796705-B2 | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170008879-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2017-01-12 | — | — | US | disclosed |
| US-9096725-B2 | Cross-linked polyazole, method of preparing the polyazole, electrode for fuel cell including the cross-linked polyazole, electrolyte membrane for fuel cell including the cross-linked polyazole, method of manufacturing the electrolyte membrane, and fuel cell including the cross-linked polyazole | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2015-08-04 | — | — | US | disclosed |
| US-9096725-B2 | Cross-linked polyazole, method of preparing the polyazole, electrode for fuel cell including the cross-linked polyazole, electrolyte membrane for fuel cell including the cross-linked polyazole, method of manufacturing the electrolyte membrane, and fuel cell including the cross-linked polyazole | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2015-08-04 | — | — | US | disclosed |
| US-20130156731-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEAS | SCHERING CORPORATION | 2013-06-20 | — | — | US | disclosed |
| US-20110223134-A1 | FUSED TRICYCLIC SILYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME LLC | 2011-09-15 | — | — | US | disclosed |
| US-20100273087-A1 | CROSS-LINKED POLYAZOLE, METHOD OF PREPARING THE POLYAZOLE, ELECTRODE FOR FUEL CELL INCLUDING THE CROSS-LINKED POLYAZOLE, ELECTROLYTE MEMBRANE FOR FUEL CELL INCLUDING THE CROSS-LINKED POLYAZOLE, METHOD OF MANUFACTURING THE ELECTROLYTE MEMBRANE, AND FUEL CELL INCLUDING THE CROSS-LINKED POLYAZOLE | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2010-10-28 | — | — | US | disclosed |
| US-20100273087-A1 | CROSS-LINKED POLYAZOLE, METHOD OF PREPARING THE POLYAZOLE, ELECTRODE FOR FUEL CELL INCLUDING THE CROSS-LINKED POLYAZOLE, ELECTROLYTE MEMBRANE FOR FUEL CELL INCLUDING THE CROSS-LINKED POLYAZOLE, METHOD OF MANUFACTURING THE ELECTROLYTE MEMBRANE, AND FUEL CELL INCLUDING THE CROSS-LINKED POLYAZOLE | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130156731-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEAS | HAVCR2, ELOC, ZC3HAV1 | TYMS 747/4885MAOA 783/4885CYP1A2 364/4885 |
| US-20170008879-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | ZC3HAV1, HAVCR2, ZC3HAV1L | TYMS 249/4885MAOA 2432/4885CYP1A2 1816/4885 |
| US-20110223134-A1 | FUSED TRICYCLIC SILYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | FOXM1, ZC3HAV1L, C1S | TYMS 1195/4885MAOA 2188/4885CYP1A2 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.